Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Comparison of Self-Expanding Bioprostheses for Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis: SCOPE 2 Randomized Clinical Trial

Open access
Tamburino, Corrado, Bleiziffer, Sabine, Thiele, Holger, Scholtz, Smita, Hildick-Smith, David, Cunnington, Michael, Wolf, Alexander, Barbanti, Marco, Tchetchè, Didier, Garot, Philippe, Pagnotta, Paolo, Gilard, Martine, Bedogni, Francesco, Van Belle, Eric, Vasa-Nicotera, Mariuca, Chieffo, Alaide, Deutsch, Oliver, Kempfert, Jörg, Søndergaard, Lars, Butter, Christian, Trillo-Nouche, Ramiro, Lotfi, Shahram, Möllmann, Helge, Joner, Michael, Abdel-Wahab, Mohamed, Bogaerts, Kris, Hengstenberg, Christian, Capodanno, Davide · 2020 · Circulation

Abstract

Background: Few randomized trials have compared bioprostheses for transcatheter aortic valve replacement, and no trials have compared bioprostheses with supra-annular design. The SCOPE 2 trial (Safety and Efficacy Comparison of Two TAVI Systems in a Prospective Randomized Evaluation 2) was designed to compare the clinical outcomes of the ACURATE neo and CoreValve Evolut bioprostheses for transcatheter aortic valve replacement. Methods: SCOPE 2 was a randomized trial performed at 23 centers in 6 countries between April 2017 and April 2019. Patients ≥75 years old with an indication for transfemoral transcatheter aortic valve replacement as agreed by the heart team were randomly assigned to receive treatment with either the ACURATE neo (n=398) or the CoreValve Evolut bioprostheses (n=398). The primary end point, powered for noninferiority of the ACURATE neo bioprosthesis, was all-cause death or stroke at 1 year. The key secondary end point, powered for superiority of the ACURATE neo bioprosthesis, was new permanent pacemaker implantation at 30 days. Results: Among 796 randomized patients (mean age, 83.2±4.3 years; mean Society of Thoracic Surgeons Predicted Risk of Mortality score, 4.6±2.9%), clinical follow-up information was available for 778 (98%) patients. Within 1 year, the primary end point occurred in 15.8% of patients in the ACURATE neo group and in 13.9% of patients in the CoreValve Evolut group (absolute risk difference, 1.8%, upper 1-sided 95% confidence limit, 6.1%; P =0.0549 for noninferiority). The 30-day rates of new permanent pacemaker implantation were 10.5% in the ACURATE neo group and 18.0% in the CoreValve Evolut group (absolute risk difference, –7.5% [95% CI, –12.4 to –2.60]; P =0.0027). No significant differences were observed in the components of the primary end point. Cardiac death at 30 days (2.8% versus 0.8%; P =0.03) and 1 year (8.4% versus 3.9%; P =0.01), and moderate or severe aortic regurgitation at 30 days (10% versus 3%; P =0.002) were significantly increased in the ACURATE neo group. Conclusions: Transfemoral transcatheter aortic valve replacement with the self-expanding ACURATE neo did not meet noninferiority compared with the self-expanding CoreValve Evolut in terms of all-cause death or stroke at 1 year, and it was associated with a lower incidence of new permanent pacemaker implantation. In secondary analyses, the ACURATE neo was associated with more moderate or severe aortic regurgitation at 30 days and cardiac death at 30 days and 1 year. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03192813.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.120.051547

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 170

Metadata

Authors
Tamburino, C., Bleiziffer, S., Thiele, H., Scholtz, S., Hildick-Smith, D., Cunnington, M., Wolf, A., Barbanti, M., Tchetchè, D., Garot, P., Pagnotta, P., Gilard, M., Bedogni, F., Van Belle, E., Vasa-Nicotera, M., Chieffo, A., Deutsch, O., Kempfert, J., Søndergaard, L., Butter, C., Trillo-Nouche, R., Lotfi, S., Möllmann, H., Joner, M., Abdel-Wahab, M., Bogaerts, K., Hengstenberg, C., & Capodanno, D.
Venue
Circulation
Published
2020-12-22
Volume
142
Issue
25
Pages
2431-2442
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W3093249073
Cited by
170
References
3
FWCI
12.71
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of Self-Expanding Bioprostheses for Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis: SCOPE 2 Randomized Clinical Trial. https://app.cochat.ai/papers/10.1161/circulationaha.120.051547
The paper
Tamburino, C., Bleiziffer, S., Thiele, H., Scholtz, S., Hildick-Smith, D., Cunnington, M., Wolf, A., Barbanti, M., Tchetchè, D., Garot, P., Pagnotta, P., Gilard, M., Bedogni, F., Van Belle, E., Vasa-Nicotera, M., Chieffo, A., Deutsch, O., Kempfert, J., Søndergaard, L., . . . Capodanno, D. (2020). Comparison of Self-Expanding Bioprostheses for Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis: SCOPE 2 Randomized Clinical Trial. Circulation. https://doi.org/10.1161/circulationaha.120.051547

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.